Home › Compare › ENSRF vs ABBV
ENSRF yields 2000000.00% · ABBV yields 3.06%● Live data
📍 ENSRF pulled ahead of the other in Year 1
Combined, ENSRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENSRF + ABBV for your $10,000?
Enseco Energy Services Corp., together with its subsidiaries, provides energy related services and rentals to the upstream oil and gas industry in Canada and the United States. The company offers directional and horizontal drilling services; production testing; and frac flowback services. It provides drilling tools and services, such as performance drilling motors; electromagnetic, negative pulse, enseco edge positive pulse, Gamma-Ray LWD, and resistivity measurement tools; drilling motor facilities; and well planning and directional modeling torques and drags, as well as BHA design, anti-collision analysis, and repair and manufacturing services. The company's production services product line includes p-tanks, frac flowback, in-line testing, bleed offs, stimulation recovery, sour service capability, portable and skid mounted configurations, zero ground disturbance flare stacks and office trailers, flow lines rated to 10,000 psi, and vessels rated from 200 to 1,440 psi. In addition, it offers well stimulation frac flowback services; and oil and gas production testing. Enseco Energy Services Corp. was incorporated in 2006 and is based in Calgary, Canada.
Full ENSRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.